Creating a database to improve drug testing for underrepresented populations
Official title: Addressing health disparities through a quantitative physiological database and precision systems modeling
Funded at Precision Quantomics INC · NIH-10923431 · Data updated 2026-11-12
This study is working to make sure that new medicines are safe and effective for everyone, including kids, women, and people from different racial backgrounds, by gathering important health data from these groups to improve how we understand how drugs work in their bodies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Precision Quantomics INC NIH-funded |
| Lab location | 1 site (Spokane, United States) |
| Project start | August 11, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $294,450 |
| NIH project number | 1R41MD019585-01 |
| Project ID | NIH-10923431 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children, women, elderly individuals, and racial minorities who have historically been excluded from drug testing.
✕Less likely to help
Patients who do not belong to underrepresented populations or those who are not involved in drug development may not receive direct benefits from this research.
What this research studies
This research aims to address health disparities in drug development by creating a quantitative physiological database that includes data from underrepresented populations such as children, women, and racial minorities. The project will utilize physiologically-based pharmacokinetic (PBPK) modeling to better understand how drugs behave in these diverse groups. By incorporating physiological data and drug metabolism information specific to these populations, the research seeks to enhance the accuracy of drug testing and evaluation. This approach is designed to ensure that drugs are safe and effective for everyone, not just the majority population.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective medications for underrepresented populations, reducing health disparities.
How similar studies have gone: While the use of PBPK modeling is gaining traction, this specific approach to include underrepresented populations is relatively novel and has not been extensively tested.
Where this research is happening
-
Precision Quantomics INC
Spokane, United States Active
Researchers
- Principal investigator: Watson, Christy J.w. — Precision Quantomics INC
- Study coordinator: Watson, Christy J.w.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.